Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A novel NMDA receptor-based intervention to suppress compulsion-like alcohol drinking.

Wegner SA, Hu B, De Oliveira Sergio T, Darevsky D, Kwok CC, Lei K, Hopf FW.

Neuropharmacology. 2019 Oct;157:107681. doi: 10.1016/j.neuropharm.2019.107681. Epub 2019 Jun 25.

PMID:
31251994
2.

Nucleus Accumbens Shell Orexin-1 Receptors Are Critical Mediators of Binge Intake in Excessive-Drinking Individuals.

Lei K, Kwok C, Darevsky D, Wegner SA, Yu J, Nakayama L, Pedrozo V, Anderson L, Ghotra S, Fouad M, Hopf FW.

Front Neurosci. 2019 Feb 13;13:88. doi: 10.3389/fnins.2019.00088. eCollection 2019.

3.

An outlook on self-assessment of homework assignments in higher mathematics education.

Beumann S, Wegner SA.

Int J STEM Educ. 2018;5(1):55. doi: 10.1186/s40594-018-0146-z. Epub 2018 Dec 27.

4.

Drinking despite adversity: behavioral evidence for a head down and push strategy of conflict-resistant alcohol drinking in rats.

Darevsky D, Gill TM, Vitale KR, Hu B, Wegner SA, Hopf FW.

Addict Biol. 2019 May;24(3):426-437. doi: 10.1111/adb.12608. Epub 2018 Mar 8.

PMID:
29516676
5.

Limited Excessive Voluntary Alcohol Drinking Leads to Liver Dysfunction in Mice.

Wegner SA, Pollard KA, Kharazia V, Darevsky D, Perez L, Roychowdhury S, Xu A, Ron D, Nagy LE, Hopf FW.

Alcohol Clin Exp Res. 2017 Feb;41(2):345-358. doi: 10.1111/acer.13303. Epub 2017 Jan 19.

6.

A single alcohol drinking session is sufficient to enable subsequent aversion-resistant consumption in mice.

Lei K, Wegner SA, Yu JH, Simms JA, Hopf FW.

Alcohol. 2016 Sep;55:9-16. doi: 10.1016/j.alcohol.2016.07.008. Epub 2016 Aug 20.

7.

Nucleus Accumbens Shell and mPFC but Not Insula Orexin-1 Receptors Promote Excessive Alcohol Drinking.

Lei K, Wegner SA, Yu JH, Mototake A, Hu B, Hopf FW.

Front Neurosci. 2016 Aug 30;10:400. doi: 10.3389/fnins.2016.00400. eCollection 2016.

8.

Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice.

Lei K, Wegner SA, Yu JH, Hopf FW.

Neuropharmacology. 2016 Nov;110(Pt A):431-437. doi: 10.1016/j.neuropharm.2016.08.008. Epub 2016 Aug 11.

9.

The First Alcohol Drink Triggers mTORC1-Dependent Synaptic Plasticity in Nucleus Accumbens Dopamine D1 Receptor Neurons.

Beckley JT, Laguesse S, Phamluong K, Morisot N, Wegner SA, Ron D.

J Neurosci. 2016 Jan 20;36(3):701-13. doi: 10.1523/JNEUROSCI.2254-15.2016. Erratum in: J Neurosci. 2016 Apr 13;36(15):4400-3.

10.

Striatal-enriched protein tyrosine phosphatase controls responses to aversive stimuli: implication for ethanol drinking.

Legastelois R, Darcq E, Wegner SA, Lombroso PJ, Ron D.

PLoS One. 2015 May 20;10(5):e0127408. doi: 10.1371/journal.pone.0127408. eCollection 2015.

11.

mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample task.

LaCrosse AL, Burrows BT, Angulo RM, Conrad PR, Himes SM, Mathews N, Wegner SA, Taylor SB, Olive MF.

Psychopharmacology (Berl). 2015 Jan;232(1):251-8. doi: 10.1007/s00213-014-3653-8. Epub 2014 Jun 29.

12.

Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART.

Weintrob AC, Fieberg AM, Agan BK, Ganesan A, Crum-Cianflone NF, Marconi VC, Roediger M, Fraser SL, Wegner SA, Wortmann GW.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):40-7. doi: 10.1097/QAI.0b013e31817bec05.

PMID:
18667932
13.

Effectiveness of highly-active antiretroviral therapy by race/ethnicity.

Silverberg MJ, Wegner SA, Milazzo MJ, McKaig RG, Williams CF, Agan BK, Armstrong AW, Gange SJ, Hawkes C, O'Connell RJ, Ahuja SK, Dolan MJ; Tri-Service AIDS Clinical Consortium Natural History Study Group.

AIDS. 2006 Jul 13;20(11):1531-8.

PMID:
16847408
14.

Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance.

Kijak GH, Currier JR, Tovanabutra S, Cox JH, Michael NL, Wegner SA, Birx DL, McCutchan FE.

AIDS Rev. 2004 Jan-Mar;6(1):54-60. Review.

PMID:
15168741
15.

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.

Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL; RV-125 Centers for Education and Research on Therapeutics Study Team.

Clin Infect Dis. 2004 Mar 1;38(5):723-30. Epub 2004 Feb 6.

PMID:
14986258
16.

Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort.

Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR, McCutchan FE.

AIDS. 2003 Nov 21;17(17):2521-7.

PMID:
14600525
17.

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA.

AIDS. 2001 Sep 7;15(13):1671-7.

PMID:
11546942
18.

Clinical implications of identifying non-B subtypes of human immunodeficiency virus type 1 infection.

Walter EA, Gilliam B, Delmar JA, Spooner K, Morris JT, Aronson N, Wegner SA, Michael NL, Jagodzinski LL.

Clin Infect Dis. 2000 Sep;31(3):798-802. Epub 2000 Oct 4.

PMID:
11017832
19.

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B.

AIDS. 2000 May 26;14(8):1009-15.

PMID:
10853983
20.

Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms.

Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, Vickerman P, Bloor S, Larder B, Michael NL, Wegner SA.

J Clin Microbiol. 1999 Aug;37(8):2533-7.

21.

CXCR4 polymorphisms and HIV-1 pathogenesis.

Martin MP, Carrington M, Dean M, O'Brien SJ, Sheppard HW, Wegner SA, Michael NL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):430. No abstract available.

PMID:
9833755
22.

Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1.

Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL.

J Biol Chem. 1998 Feb 20;273(8):4754-60.

23.

Treatment of chronic graft-versus-host disease with clofazimine.

Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH.

Blood. 1997 Apr 1;89(7):2298-302.

24.

Sampling lymph node content of human immunodeficiency virus type 1 nucleic acids and p24 antigen by fine-needle aspiration in early-stage patients.

Anderson DW, DeNobile J, Zhao F, Vahey M, Lane J, Nau M, Brown AE, Wegner SA, Malone JD, Wagner K, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S57-61.

PMID:
7552514

Supplemental Content

Loading ...
Support Center